Clinical Trial Update: CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

View source ↗

Summary

A ClinicalTrials.gov entry sponsored by AstraZeneca describes the CHOICE study evaluating decision factors for EGFR-TKI therapy in Chinese patients with stage I…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR-TKI (EGFR tyrosine kinase inhibitor)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Status: RECRUITING